Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

• 主要な著者: Antonio Lacquaniti (著者), Patrizio Pasqualetti (著者), Teresa Casuscelli di Tocco (著者), Susanna Campo (著者), Stefania Rovito (著者), Maurizio Bucca (著者), Antonino Ragusa (著者), Paolo Monardo (著者)
• フォーマット: 図書
• 出版事項: The Korean Society of Nephrology, 2020-09-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...